Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 18, 2003. The report serves as a notification of changes in director interests regarding the company's Ordinary Shares and American Depositary Receipts (ADRs) held within the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding movements within an employee retirement fund rather than corporate financial performance.
Material Changes
The report details two specific movements in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan:
- March 13, 2003: Holdings decreased from 18,507,017 to 18,435,287 ADRs at an average price of $34.88.
- March 14, 2003: Holdings increased from 18,435,287 to 18,698,323 ADRs at an average price of $35.58.
These changes affect the potential interest of Director Dr. J P Garnier, as he is a beneficiary of the discretionary fund alongside other employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is a compliance report regarding director share interests.
Key Facts for Investor Verification
- Director Dr. J P Garnier holds a potential interest in the GlaxoSmithKline US Retirement Savings Plan.
- The Plan's ADR holdings fluctuated by approximately 263,000 shares between March 13 and March 14, 2003.
- The average transaction prices for these movements were $34.88 and $35.58, respectively.
- This filing does not contain financial results or operational updates for the company.